Charlie Nicholls
Publications by Year
Research Areas
Diabetes Management and Research, Diabetes Treatment and Management, Health Systems, Economic Evaluations, Quality of Life, Hyperglycemia and glycemic control in critically ill and hospitalized patients, Hematopoietic Stem Cell Transplantation
Most-Cited Works
- Waterborne outbreak of Campylobacter jejuni in Christchurch: the importance of a combined epidemiologic and microbiologic investigation.(1991)
- → Introducing PIONEER: a project to harness big data in prostate cancer research(2020)39 cited
- → Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study(2019)29 cited
- → Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial(2022)18 cited
- → Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting(2019)8 cited
- → Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study(2020)7 cited
- → Real‐world outcomes of addition of insulin glargine 300 U/ mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study(2022)7 cited
- → Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study(2021)5 cited
- → Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research(2020)5 cited
- → How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?(2020)5 cited